Dexcom (Nasdaq:DXCM) announced today that it appointed Rimma Driscoll to its board of directors.
The San Diego-based continuous glucose monitor (CGM) maker made Driscoll’s appointment effective on Aug. 24. She currently serves as EVP and head of global strategy, commercial and business development and global biodevices for Zoetis.
At Zoetis, a leading animal health company and a Fortune 500 member, Driscoll oversees the global business strategy. She manages the execution of commercial launch plans, external business development and integration efforts. Dexcom said in a news release that she brings a track record of impactful leadership across the global healthcare, consumer and animal health industries. Her past experience includes the successful completion of a number of transformative transactions and key product launches.
“We are very excited to welcome Rimma to the Dexcom board,” said Kevin Sayer, chair, president and CEO at Dexcom. “Her strategic guidance at Zoetis and Procter & Gamble has been instrumental in helping these two global organizations achieve and grow their market leadership positions. As we continue to extend access to Dexcom’s real-time CGM systems to more people throughout the world, we look forward to benefiting from Rimma’s experience navigating global commercial markets and key strategic partnerships.”
At Zoetis, Driscoll’s past roles include SVP and head of global business development, business integrations and strategic alliances. She held that post from 2020 to 2022, before she joined the executive leadership team. Additionally, she served as VP and head of global business development and strategic alliances from 2016 to 2020.
Before joining Zoetis, Driscoll held a number of positions of increasing responsibility at Procter & Gamble from 1994 to 2016. She established and led the company’s global business development group in Geneva, Switzerland as well.